U.S. Genomics Unveils Trilogy 2020 Single Molecule Analyzer; First Commercial Bench-Top Technology To Directly Detect Individual miRNA Molecules without Amplification.
WOBURN, Mass. -- U.S. Genomics(TM), a pioneer of single molecule biology tools for the life sciences industry, today unveiled its Trilogy(TM) 2020 Single Molecule Analyzer. The bench-top technology platform, composed of instrumentation, reagents and software, is the first commercial technology to directly detect and quantitate individual molecules without amplification. With quantitation of single molecules, scientists can perform more accurate and thorough genetic, functional genomic, and diagnostic research at the single molecule level.
Conventional technologies study millions of molecules at a time and rely on amplification and measurement of bulk fluorescence. These methods are known to create inherent errors and can undermine a researcher's ability to achieve accurate, quantitative results. The Trilogy 2020 Single Molecule Analyzer uniquely combines advances in microfluidics, optical engineering, and labeling strategies to eliminate the bias of amplification. As a result, researchers can now accurately examine how cellular elements function and interact within biological pathways.
"The launch of the Trilogy 2020 Single Molecule Analyzer is a significant milestone for our company and the future of biodiscovery," said Stephen P. DeFalco, Chairman and CEO of U.S. Genomics. "Researchers for the first time can utilize single molecule sensitivity to accurately study molecular interactions and disease pathways."
The initial application for the Trilogy 2020 Single Molecule Analyzer is for the direct detection of microRNA (miRNA) molecules. This molecular group plays a critical role in cell development and has been recently linked to cancer and other major diseases. Known to be difficult and often impossible to amplify, miRNAs regulate the level and activity of other RNAs in the cell. With U.S. Genomics' library of Direct(TM) miRNA assays and the Trilogy 2020 Single Molecule Analyzer, researchers can now easily characterize and quantitate target miRNAs of interest.
The new Trilogy 2020 Single Molecule Analyzer accommodates 96- and 384-well plates and can process up to 2000 biological samples per day. The system is compatible with a range of liquid handling robots. Advanced software streamlines plate and protocol set-up and offers flexible data analysis for rapid results.
The Trilogy 2020 Single Molecule Analyzer will be shown at the 2005 meeting of the Federation of American Societies for Experimental Biology (FASEB), booth # 539, April 2-6 at the San Diego Convention Center. In addition, the company will showcase the new system at the American Association for Cancer Research (AACR) Annual Meeting, booth # 226, to be held April 16-20 at the Anaheim Convention Center.
